Complexes of Ruthenium(II) as Promising Dual-Active Agents against Cancer and Viral Infections-Reference-Cited by-同舟云学术

Complexes of Ruthenium(II) as Promising Dual-Active Agents against Cancer and Viral Infections

Published:2023-12-15 Issue:12 Volume:16 Page:1729
ISSN:1424-8247
Container-title:Pharmaceuticals
language:en
Short-container-title:Pharmaceuticals

Author:

D’Amato Assunta¹^ORCID,Mariconda Annaluisa²^ORCID,Iacopetta Domenico³^ORCID,Ceramella Jessica³^ORCID,Catalano Alessia⁴^ORCID,Sinicropi Maria Stefania³^ORCID,Longo Pasquale¹^ORCID

Affiliation:

1. Department of Chemistry and Biology, University of Salerno, Via Giovanni Paolo II, 132, 84084 Fisciano, Italy

2. Department of Science, University of Basilicata, 85100 Potenza, Italy

3. Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Arcavacata di Rende, Italy

4. Department of Pharmacy-Drug Sciences, University of Bari “Aldo Moro”, 70126 Bari, Italy

Abstract

Poor responses to medical care and the failure of pharmacological treatment for many high-frequency diseases, such as cancer and viral infections, have been widely documented. In this context, numerous metal-based substances, including cisplatin, auranofin, various gold metallodrugs, and ruthenium complexes, are under study as possible anticancer and antiviral agents. The two Ru(III) and Ru(II) complexes, namely, BOLD-100 and RAPTA-C, are presently being studied in a clinical trial and preclinical studies evaluation, respectively, as anticancer agents. Interestingly, BOLD-100 has also recently demonstrated antiviral activity against SARS-CoV-2, which is the virus responsible for the COVID-19 pandemic. Over the last years, much effort has been dedicated to discovering new dual anticancer–antiviral agents. Ru-based complexes could be very suitable in this respect. Thus, this review focuses on the most recent studies regarding newly synthesized Ru(II) complexes for use as anticancer and/or antiviral agents.

Funder

PRIN 2022

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://www.mdpi.com/1424-8247/16/12/1729/pdf

Reference159 articles.

1. Recent advancements in coordination compounds and their potential clinical application in the management of diseases: An up-to-date review;Singh;Polyhedron,2023

2. Metallotherapeutic complexes with high selective properties for anti-neoplastic therapy;De;Coord. Chem. Rev.,2024

3. Gamberi, T., and Hanif, M. (2022). Metal-based complexes in cancer treatment. Biomedicines, 10.

4. Latest developments in metal complexes as anticancer agents;Paprocka;Coord. Chem. Rev.,2022

5. Ceramella, J., Mariconda, A., Sirignano, M., Iacopetta, D., Rosano, C., Catalano, A., Saturnino, C., Sinicropi, M.S., and Longo, P. (2022). Novel Au carbene complexes as promising multi-target agents in breast cancer treatment. Pharmaceuticals, 15.